FIELD: medicine.
SUBSTANCE: claimed is the application of N-(2-adamantyl)-hexamethylenimine hydrochloride (himantane) as a medication for treating cerebral circulation disorders and brain traumas. An ability of himantane to reduce animal morbidity and increase cognitive and motor indices in case of its introduction after 3.5 hours after modelling a hematoma in rats and further introduction for 4 days was determined, which testifies to its possessing the neuroprotective potential on the model of the intracerebral post-traumatic hematoma. The technical result consists in the realisation of the claimed purpose: it has been shown that himantane in a dose of 5 mg/kg in case of intravenous introduction causes the increase of cerebral circulation in the rats' brain after ischemic brain affection without changing the level of arterial pressure.
EFFECT: medication did not produce a significant impact on the blood supply of the brain of the intact animals and did not cause a change in the heart rate and respiratory rate.
1 dwg, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SUCCINIC ACID ESTERS OF 5-HYDROXYADAMANTAN-2-ONE, IMPROVING BLOOD SUPPLY TO ISCHEMIC BRAIN | 2017 |
|
RU2658833C1 |
| AGENT FOR TREATMENT OF ACUTE AND CHRONIC DISTURBANCES OF CEREBRAL CIRCULATION, INCLUDING STROKE ON BASIS OF HYDROGENATED PYRIDO (4,3-b)INDOLES (VERSIONS), PHARMACOLOGICAL AGENT ON ITS BASIS AND METHOD OF ITS APPLICATION | 2006 |
|
RU2340342C2 |
| SUBSTANCE OF NEUROTROPIC- NEUROREGULATING ACTIVITY | 2006 |
|
RU2329804C2 |
| METHOD OF TREATING CRANIOCEREBRAL INJURY AND AGENT FOR IMPLEMENTATION THEREOF | 2023 |
|
RU2826364C1 |
| INJECTION DOSAGE FORM FOR ACUTE STROKE TREATMENT, METHOD OF PRODUCTION AND APPLICATION THEREOF | 2005 |
|
RU2330680C2 |
| METHOD FOR PREPARING COMPLEX OF BIOLOGICALLY ACTIVE POLYPEPTIDES FOR NORMALIZATION OF BRAIN FUNCTION AND PHARMACEUTICAL AGENT BASED ON THEREOF | 2004 |
|
RU2275924C2 |
| AGENT POSSESSING ENDOTHELIUM PROTECTIVE EFFECT IN CONDITIONS OF EXPERIMENTAL DIABETES MELLITUS AND CEREBRAL BLOOD CIRCULATION DISORDER | 2015 |
|
RU2601622C1 |
| DRUG WITH COMPLEX PHARMACOLOGICAL EFFECT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES, CORRECTION OF CEREBRAL CIRCULATION DISORDERS, TREATMENT OF CONSEQUENCES OF CEREBROVASCULAR DISEASES (OPTIONS) | 2019 |
|
RU2757874C1 |
| DERIVATIVES OF QUINAZOLINE-4 (3H)-ONE, WITH NEURO- AND CARDIOPROTECTIVE ACTIVITY | 2016 |
|
RU2622638C1 |
| ACYLHYDRAZONE (2,3,4-TRIMETHOXY-N'-(8-METHYL-8-AZABICYCLO[3.2.1.]OCTANE-3-YLIDENE) BENZOHYDRAZIDE HYDROCHLORIDE), HAVING ANTIMIGRAINE AND ANXIOLYTIC ACTIVITY | 2016 |
|
RU2699658C2 |
